Abstract
Immune Responses Induced by Candidate Optimized HIV DNA Vaccine in Phase I Clinical Trial
Highlights
The human immunodeficiency virus (HIV) vaccine is urgently needed to curtail the global AIDS epidemic
The results obtained in RV144 clinic trial of a canarypox vector prime/gp120 protein boost vaccine for HIV-1 suggest that neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations
It is known that T cells, CD8+ T cells, exert some control over HIV-1 viremia and progression to disease in natural infection
Summary
The human immunodeficiency virus (HIV) vaccine is urgently needed to curtail the global AIDS epidemic. That is why the induction of HIV-specific cell-mediated immunity may be necessary for preventive HIV vaccine, in combination with induction of neutralizing antibodies.is associated with the Volume 1 Issue 1 1000108. Resistance to disease in these patients and resistance to infection in highly exposed seronegative patients is associated with different combinations of human leukocyte antigen (HLA) [7, 8] as well as with the detection of HIV-1specific CD8+ T cells [9, 10]. That is why the induction of HIVspecific cell-mediated immunity may be necessary for preventive HIV vaccine, in combination with induction of neutralizing antibodies. We report the findings from the Phase I clinical trial of a candidate multigene HIV-1 clade A DNA vaccine and demonstrate the induction of HIV-1–specific immune responses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
